Impact of Age or Sex on Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Gel in Participants with Moderate-to-Severe Acne

Main Article Content

Linda Stein Gold, MD
Leon H. Kircik, MD
William Philip Werschler, MD
Hilary Baldwin, MD
Valerie Callender, MD
Lawrence Green, MD
Neil Sadick, MD
Jeffrey L. Sugarman, MD, PhD
Zoe D Draelos, MD
Emil A Tanghetti, MD
Neal Bhatia, MD


Pediatric, Adult, Acne, Male, Female, Retinoid, BPO, Adapalene, Clindamycin, Antibiotic, Combination


Introduction: IDP-126 (clindamycin phosphate 1.2%/benzoyl peroxide [BPO] 3.1%/adapalene 0.15%) polymeric mesh gel is the first triple-combination, fixed-dose topical acne treatment in development. IDP-126 demonstrated superior efficacy to vehicle and component dyads, with good safety/tolerability, in a phase 2 and two phase 3 studies of participants with moderate-to-severe acne. The objective of this analysis was to assess the impact of age or sex on efficacy and safety/tolerability of IDP-126 gel.

Methods: This post hoc analysis evaluated effect of age or sex on efficacy/safety of IDP-126 using data pooled from two phase 3, double-blind, randomized, 12-week studies (NCT04214639, N=183; NCT04214652, N=180). Participants aged ≥9 years with moderate-to-severe acne were randomized 2:1 to once-daily IDP-126 gel or vehicle gel. Data were analyzed by age (pediatric [9-17 years]: n=178; adult [≥18 years]: n=185) or sex (females: n=212; males: n=151). Endpoints included ≥2-grade reduction from baseline in Evaluator’s Global Severity Score and clear/almost clear skin (treatment success) and least-squares mean percent change from baseline in inflammatory and noninflammatory lesion counts. Treatment-emergent adverse events (TEAEs) were also assessed.

Results: At week 12, over half of pediatric and almost half of adult IDP-126-treated participants achieved treatment success (52.7% and 45.9%, respectively) versus one-fourth with vehicle (24.0% and 23.5%; P<0.01, both). Results by sex were similar (IDP‑126 vs vehicle: females: 53.7% vs 23.0%; males: 43.1% vs 24.6%; P<0.05, both). IDP‑126 provided >70% reductions in inflammatory and noninflammatory lesions in all subgroups, versus 41%-63% with vehicle (P≤0.001, all). Differences between sex or age groups were not statistically significant. Most TEAEs were of mild-moderate severity in all groups.

Conclusions: Fixed-dose, triple-combination IDP-126 gel was efficacious and well tolerated in participants with moderate-to-severe acne, regardless of age or sex, with approximately half of participants achieving clear/almost clear skin.

Funding: Ortho Dermatologics


1. Tanghetti E. J Drugs Dermatol. 2012;11(12):1417-1421.

2. Stein Gold L. J Drugs Dermatol. 2019;18(12):1218-1225.

3. Cook-Bolden F. J Drugs Dermatol. 2020;19(1):78-85.

4. Hester C, et al. Pediatr Dermatol. 2016;33(1):49-55.

5. Kraft J and Freiman A. CMAJ. 2011; 183(7):E430-435.

6. Zeichner JA, et al. J Clin Aesthet Dermatol. 2017;10(1):37-46.

7. Stein Gold L, et al. Am J Clin Dermatol. 2022;23(1):93-104.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>